Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer. * Prior first line therapy with a platinum and taxane based combination as adjuvant therapy * Measurable disease defined by RECIST criteria * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * age \> 18 * Karnofsky performance status \> 70 * Up to three prior lines of cytotoxic therapy in the setting of recurrent disease. * Estimated life expectancy of at least 3 months * Women of child-bearing potential must have a negative pregnancy test * Adequate hematopoietic function defined as: * ANC ≥ 1500/mm3 * Platelets ≥ 100,000/mm3 * Hemoglobin ≥ 9 g/dL * Magnesium ≥ lower limit of normal * Calcium ≥ lower limit of normal * Adequate renal and hepatic function defined as: * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * SGOT ≤ 3 times ULN * Alanine aminotransferase (ALT) ≤3xULN (if liver metastases ≤5xULN) * Alkaline phosphatase ≤ 3 times ULN * Creatinine ≤ 1.5 mg/dL times ULN * Creatinine clearance ≤ 50 mL/min Exclusion Criteria: * Prior anti-EGFr antibody therapy (e.g., cetuximab) or treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib, lapatinib) * Prior treatment with gemcitabine * Radiotherapy ≤ 14 days prior to enrollment. * More than three lines of systemic chemotherapy for recurrent or advanced disease. Prior hormonal therapy is allowed. * Prior immunotherapy, or experimental or approved proteins/antibodies * Female subject is pregnant or breast-feeding. * Patient has received other investigational drugs within 28 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Prior treatment with panitumumab * Concurrent uncontrolled illness * Ongoing or active infection * History or active secondary cancer within the last 5 years, except for superficial basal cell skin cancers, curatively resected non-melanoma skin cancer * Psychiatric illness or social situation that would preclude study compliance. * History or known presence of central nervous system (CNS) metastasis * Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine) * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) \< 1 year before randomization * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan * Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection * Major surgery within 28 days or minor surgery within 14 days of study enrollment